Optimal Control of Drug Therapy in a Hepatitis B Model
AbstractCombination antiviral drug therapy improves the survival rates of patients chronically infected with hepatitis B virus by controlling viral replication and enhancing immune responses. Some of these drugs have side effects that make them unsuitable for long-term administration. To address the trade-off between the positive and negative effects of the combination therapy, we investigated an optimal control problem for a delay differential equation model of immune responses to hepatitis virus B infection. Our optimal control problem investigates the interplay between virological and immunomodulatory effects of therapy, the control of viremia and the administration of the minimal dosage over a short period of time. Our numerical results show that the high drug levels that induce immune modulation rather than suppression of virological factors are essential for the clearance of hepatitis B virus. View Full-Text
Share & Cite This Article
Forde, J.E.; Ciupe, S.M.; Cintron-Arias, A.; Lenhart, S. Optimal Control of Drug Therapy in a Hepatitis B Model. Appl. Sci. 2016, 6, 219.
Forde JE, Ciupe SM, Cintron-Arias A, Lenhart S. Optimal Control of Drug Therapy in a Hepatitis B Model. Applied Sciences. 2016; 6(8):219.Chicago/Turabian Style
Forde, Jonathan E.; Ciupe, Stanca M.; Cintron-Arias, Ariel; Lenhart, Suzanne. 2016. "Optimal Control of Drug Therapy in a Hepatitis B Model." Appl. Sci. 6, no. 8: 219.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.